Table 2. Clinical characteristics of 5-FU treated patients with and without TYMS amplification
Patient group TYMS status in metastasis Previous treatment Age, years Stage at diagnosis Metastasis size, cm Metastasis location Median survival after metastasis removal (survival range)
Group A (n = 6) Amplified 5-FU 65 I-0% 2.2 Liver-67% 329 days (109-708 days)
II-0% Lung-0%
III-33% Brain-33%
IV-50%
ND-17%
Group B (n = 21) Not amplified 5-FU 63 I-5% 3.2 Liver-80% 1,021 days (255-3,790 days)
II-10% Lung-10%
III-29% Brain-10%
IV-43%
ND-14%